
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Inovio Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$11.49 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$3.73 - US$33.79 |
---|---|
50-day moving average | US$11.6941 |
200-day moving average | US$11.9544 |
Target price | US$15.13 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-1.215 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $11.49 on 2021-02-25
1 week (2021-02-17) | N/A |
---|---|
1 month (2021-01-24) | N/A |
3 months (2020-11-24) | N/A |
6 months (2020-08-24) | N/A |
1 year (2020-02-24) | N/A |
---|---|
2 years (2019-02-24) | N/A |
3 years (2018-02-24) | N/A |
5 years (2016-02-24) | N/A |
Revenue TTM | US$2.1 million |
---|---|
Gross profit TTM | US$-82,005,389 |
Return on assets TTM | -26.14% |
Return on equity TTM | -100.68% |
Profit margin | 0% |
Book value | 1.933 |
Market capitalisation | US$2.4 billion |
TTM: trailing 12 months
There are currently 43.3 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 22.8% down from 56.1 million last month.
There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.
Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 14.8 million). Inovio Pharmaceuticals's SIR currently stands at 2.92. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 2920 shares are currently held short.
However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2153% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 215 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.
Find out more about how you can short Inovio Pharmaceuticals stock.
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as US$3.73 up to US$33.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.9963. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.
Steps to owning and managing Koss shares.